In summary, the combination of network pharmacological analysis in silico and in vivo experiment indicated that GQD could effectively ameliorate DSS-induced colitis, and the therapeutic effect of GQD was associated with its synergic modulation on inflammation suppression via EGFR/PI3K/AKT signaling pathway. This evidence concerns the gene EGFR and colitis.